-
Dr. Jun Zhou: Lessons from 29 Protocol Revisions in the CheckMate649 Study – A Blueprint for Clinical Trial Design in Immunotherapy
To advance the standard of care for gastrointestinal cancers in China and share the latest developments and insights, the “2024 CSCO Workshop on Standardized Diagnosis and Treatment of Gastrointestinal Cancers,” co-hosted by the Chinese Society of Clinical Oncology (CSCO), the Beijing Xisike Clinical Oncology Research Foundation, and the Hangzhou Oriental Clinical Oncology Research Center, took…
-
SABCS 2024 | Dr. Baoliang Guo: The Dilemma of Immediate vs. Delayed Surgery in Operable Breast Cancer Patients Aged 70+
With the global aging population, treatment strategies for breast cancer patients over 70 years old have garnered increasing attention. At the 2024 SABCS conference, a patient-level meta-analysis conducted by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) addressed the impact of immediate versus delayed surgery on outcomes in operable breast cancer patients aged 70+ (Abstract…
-
AASLD 2024丨Dr. Hui Wang’s Team: Serum HBV RNA and HBcrAg as Predictors of Low-Level Viremia in CHB Patients Treated with Nucleos(t)ide Analogs
This research is the first to conduct dynamic monitoring of HBV RNA and HBcrAg in CHB patients treated with NAs. The results revealed that compared to patients who achieved sustained…
-
SABCS 2024 | Clinical Symposium on Dose Optimization and Regimen Design in Breast Oncology
Advances in medical oncology for breast cancer are reshaping the approach to drug dosing and regimen design. Traditional chemotherapy development relied heavily on identifying the maximum tolerated dose (MTD)—the highest dose patients could endure without severe side effects. However, the focus in modern drug development, particularly for molecular targeted therapies, is shifting toward individualized dose…
-
ESMO Asia 2024 | Prof. Zhi Peng Deciphers DESTINY-Gastric06: ADCs Usher in a New Era for Advanced HER2-Positive Gastric Cancer Treatment
From December 6–8, 2024, the ESMO Asia Annual Meeting was held in Singapore, presenting groundbreaking research in oncology. Among the key highlights was the DESTINY-Gastric06 (DG06) study, which sparked extensive discussion. Oncology Frontier invited Prof. Zhi Peng, a leading researcher and specialist from Peking University Cancer Hospital, to share the latest findings from the DG06…
-
SABCS Broadcast | Prof. Yongmei Yin and Prof. Junjie Li Discuss Simplified Treatments for Early Breast Cancer and AI-Driven Primary Prevention
The 47th San Antonio Breast Cancer Symposium (SABCS), held from December 10–13, 2024, in San Antonio, USA, showcased the latest breakthroughs in breast cancer research, clinical practices, and technological innovations. This edition of “SABCS Broadcast” is hosted by Prof. Yongmei Yin from Jiangsu Provincial People’s Hospital, with live reporting by Prof. Junjie Li from Fudan…
-
ESMO ASIA 2024 | Prof. Yi-Long Wu Presents Positive Results of the Phase III PACIFIC-5 Trial, Offering Key Insights for Asian Patients
At the 2024 European Society for Medical Oncology Asia Congress (ESMO ASIA 2024), during the Preferred Oral Presentations on Thoracic Oncology, Professor Yilong Wu from Guangdong Provincial People’s Hospital presented the positive results of the PACIFIC-5 Phase III trial (Abstract No: LBA6). This study evaluated the efficacy of durvalumab consolidation therapy in unresectable Stage III…
-
SABCS 2024 | Educational Session: Liquid Biopsy – MRD, ctDNA, and Monitoring Treatment Response
Liquid biopsy is not a new concept in the field of breast cancer, but its clinical applications continue to evolve, requiring fresh insights into the technologies, terminology, biomarkers, and future directions. On Tuesday, December 10 (Central Time), during the “Educational Session 2: Liquid Biopsy: MRD, ctDNA, and Monitoring Response to Treatment” at the 2024 San…
Connecting Medical Expertise through Media